Announcements Trials

Browse Landscape

Phase

Status

Withdrawn 1 Unknown 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 370 Neoplasms 253 Carcinoma, Non-Small-Cell Lung 224 Prostatic Neoplasms 192 Lung Neoplasms 142 Colorectal Neoplasms 139 Neoplasm Metastasis 132 Pancreatic Neoplasms 131 Leukemia, Myeloid, Acute 126 Multiple Myeloma 123 Lymphoma 115 Carcinoma, Hepatocellular 111 Ovarian Neoplasms 98 Melanoma 97 Recurrence 93 Leukemia 89 Head and Neck Neoplasms 89 Leukemia, Lymphocytic, Chronic, B-Cell 86 Brain Neoplasms 86 Precursor Cell Lymphoblastic Leukemia-Lymphoma 79 Glioblastoma 77 Lymphoma, Non-Hodgkin 73 Squamous Cell Carcinoma of Head and Neck 71 Lymphoma, Follicular 70 Lymphoma, Large B-Cell, Diffuse 66 Colonic Neoplasms 66 Carcinoma, Renal Cell 62 Hematologic Neoplasms 59 Sarcoma 55 Glioma 53

Interventions

telotristat ethyl 1 lanreotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Interventional × Carcinoid Heart Disease × Clear all

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn

Carcinoid Heart Disease, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡